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number of incontinence and micturition episodes/day. Analyses of covariance 
were used to assess the effects of mirabegron on baseline-week 12 changes in 
WPAI. Longitudinal generalized estimating equations and Pearson correlation 
coefficients were used to assess associations between WPAI and OAB severity. 
Subgroup analyses were conducted for patients who discontinued prior OAB 
medication due to insufficient efficacy. RESULTS: Among the study sample (total 
N=858, employed N=394), mirabegron-treated patients experienced significantly 
greater improvement in TAI (12.3% vs. 6.7%, p<0.01) and greater but non-
significant improvements in absenteeism (0.2% vs. -0.5%), presenteeism (8.6% vs. 
6.0%), and TWPI (8.2% vs. 5.8%) than placebo-treated patients at week 12. . Based 
on the association analyses, 2.0%, 1.4% and 1.4% increases per additional 
incontinence episode and, 1.2%, 1.1% and 1.1% increases per additional 
micturition episode were observed in TAI, presenteeism, and TWPI respectively 
(p<0.01). Baseline-week 12 change in TAI was significantly correlated with 
changes in OAB severity (incontinence: r=0.17, micturition: r=0.11; p<0.01). 
Similar trends were observed in the patient-subgroup with prior treatment non-
response. CONCLUSIONS: Patients treated with mirabegron experience 
significantly reduced total activity impairment. Impairments in work 
productivity and activity outcomes are associated with OAB symptom severity, 
suggesting that treatments that improve symptom severity may also improve 
productivity impairment.  
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WAKING AT NIGHT TO VOID CAN HAVE A PROFOUND IMPACT ON 
PRODUCTIVITY  
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OBJECTIVES: Subjects with nocturia generally have a night-time overproduction 
of urine, i.e. problematic kidney function. The main manifestation is waking 
during the night to void (urinate). In people aged 40-64 years, the number of 
voids experienced per night correlated with increasingly poor sleep. A previous 
survey has shown that nocturia patients of working age have increased 
impairment in both work and non-work activities compared to subjects without 
nocturia. METHODS: Two clinical trials investigated the efficacy and safety of 
the orally disintegrating tablet desmopressin (Clintrials.gov – NCT01223937, 
NCT01262456). Subjects were females and males 19-87 years of age with nocturia 
(≥2 voids per night). The studies were conducted at primary and secondary care 
centers across the USA/Canada in 2010-2012. As part of the economic evaluation 
we collected work productivity data using the Work Productivity and Activity 
Impairment Questionnaire. RESULTS: There was a clear link between disease 
severity and productivity losses. For the full sample, the overall work 
productivity loss was 23.7%. Patients with on average less than 4 voids had an 
overall work productivity loss of 22.3%, which can be compared to 32.2% for 
patients with 4 voids or above per night. Impairment on free-time activities 
showed an even stronger impact from nocturia. The full sample presented an 
impairment of 33.7%. Patients with less than 4 voids presented a value of 32.9, 
whereas those with at least 4 voids per night presented an average impairment 
of 39.8%. The productivity reduction for subjects with at least 4 voids per night is 
at higher end when compared to productivity impairments for other chronic 
diseases. There also seems to be a linear relationship with number of voids per 
night. CONCLUSIONS: Nocturia has a profound effect on the quality of sleep and 
hence also productivity.  
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FREQUENCY SYMPTOMS IN UK PRIMARY CARE THE HEALTH IMPROVEMENT 
NETWORK (THIN) DATA  
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OBJECTIVES: Urinary symptoms can be managed with antimuscarinics  
(AMs) and alpha-blockers (αBs). There is currently limited real-life data on the 
pharmacological management of men with BPH. The objective was to evaluate 
treatment patterns for BPH patients with predominant urgency and frequency 
symptoms in UK primary care. METHODS: Observational study of men  
≥45 years whose recorded first diagnosis, symptom or therapy indicated BPH 
with predominant urgency and frequency between January 1, 2004 to September 
30, 2011 in THIN UK primary care data. Treatment patterns were evaluated, 
including switching (>1 different αBs/AMs) and discontinuation (no αB/AM 
prescriptions during the last six months), from start of symptoms/treatment  
to end of records/symptoms resolved. RESULTS: Of 8694 men identified  
(mean age 66.41 years, standard deviation 10.38), the majority (90.29%) received α 
B during follow-up (median two years). Of these, 81.82% were prescribed 
tamsulosin, 16.36% alfuzosin, 10.79% doxazosin, (<3% others). Proportion of α 
B discontinuation varied slightly between first-line αBs: tamsulosin 38.27% 
(N=6,033); alfuzosin 41.10% (N=876); doxazosin 36.08% (N=679). 1,160 (14.78%  
of αB-treated men) received αB and AM prescriptions within 30 days of each  
other. Of 2167 (24.93%) men receiving AM, 40.98% were prescribed  
tolterodine, 37.19% oxybutynin, 35.67% solifenacin, (<7% others). Proportion  
of AM switching and discontinuation varied between first-line AMs: tolterodine 
23.32% and 59.82% respectively (N=759); oxybutynin 24.60% and 54.70% (N=691);  
solifenacin 15.27% and 43.02% (N=537). Solifenacin had the highest average  
total duration of therapy, median 90 days (interquartile range [IQR] 30 to  
300), tolterodine 56 (IQR 28 to 224) and oxybutynin 56 (IQR 30 to 146). 
CONCLUSIONS: The majority of men were treated with αBs, mostly tamsulosin, 
and a quarter received AMs. Of AMs, the higher duration and lower  
switch and discontinuation with solifenacin possibly reflect better  
tolerability profile and adherence to treatment. However, there may be 
confounding differences in patient characteristics which could be assessed in 
future research.  
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USE OF ANTIHYPERTENSIVE DRUGS IN THE ADVANCED STAGE CHRONIC 
KIDNEY DISEASE POPULATION IN THE UNITED STATES  
Sonawane KB, Hansen RA 
Auburn University, Auburn, AL, USA  
OBJECTIVES: Advanced stage chronic kidney disease (CKD) (stages III-V) elevates 
the risk of cardiovascular mortality by 15%. Use of antihypertensives is therefore 
critical. This study estimates (1) the prevalence of advanced stage CKD in a 
representative sample of the US population, and (2) patterns of antihypertensive 
drug use in advanced stage CKD. METHODS: A retrospective cross-sectional 
analysis of 2009-2010 data from the National Health and Nutrition Examination 
Survey (NHANES) was conducted. We calculated estimated glomerular filtration 
rate (eGFR ) to classify participants as stage-III (Moderate - eGFR 30-59 
mL/min/1.73m2), stage-IV (Severe - eGFR 15-29 mL/min/1.73m2), or stage-V (Renal 
Failure -eGFR < 15 mL/min/1.73m2 ). Pregnant women and patients <18 years of 
age were excluded. Survey weights were applied to obtain national estimates. 
RESULTS: The estimated 2009-2010 prevalence of advanced stage CKD was 5.7%, 
representing 11,535,528 US adults. Of these, an estimated 10,344,775 were stage-
III (89.7%), 847,848 were stage-IV (7.4%), and 342,905 were stage-V (3.0%). The 
prevalence of advanced stage CKD was higher in females and white patients 
with a median age of 76 years. Among the advanced stage CKD population, 82.8% 
used antihypertensives. Monotherapy accounted for 24.8% of this use, while 
75.2% were on combination therapy. The most commonly used monotherapies 
were angiotensin converting enzyme inhibitors (ACE-I) (28.2%), beta blockers 
(27.5%), and diuretics (20.7%). For those on combination therapy, use of two 
diuretics (28.3%) was most common, followed by combinations of diuretic plus a 
beta-blocker (26.0%) and diuretic plus an ACE-I (23.8%). CONCLUSIONS: The 
estimated prevalence of advanced stage CKD is nearly 6% among US adults, with 
most being moderate severity. Most of these CKD patients used an 
antihypertensive, and the majority used two or more agents. Further studies are 
required to evaluate appropriateness of antihypertensive agent and associated 
cardio-protective effects.  
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OBJECTIVES: Venous thromboembolism (VTE) increases the risk of developing 
several complications, including recurrent VTE. This study quantifies the long-
term risk of complications associated with the development of an index 
recurrent VTE. METHODS: An analysis of health care insurance claims from the 
Ingenix IMPACTdatabase was conducted. Between January 2004 and September 
2008, subjects aged ≥18 years on the date of first recurrent VTE diagnosis 
requiring hospitalization (index recurrent deep vein thrombosis [DVT], 
pulmonary embolism [PE], or both) with ≥ 12 months of baseline observation 
prior to the index recurrent VTE were matched 1:1 with control VTE patients 
without recurrence, based on exact matching factors and propensity scores. The 
risk of developing thrombocytopenia, superficial venous thrombosis, venous 
ulcer, pulmonary hypertension, stasis dermatitis, and venous insufficiency for 
up to 1 year after the index recurrent VTE event was compared between the 
recurrent VTE and the VTE control group. RESULTS: The recurrent VTE and VTE 
cohorts (8,001 subjects in each group) were well-matched with respect to age, 
gender, comorbidities, and VTE risk factors distributions. The absolute risks of 
developing thrombocytopenia, superficial venous thrombosis, venous ulcer, 
pulmonary hypertension, stasis dermatitis, and venous insufficiency were 7.1%, 
4.4%, 1.5%, 5.3%, 1.4%, and 7.2% for the recurrent VTE group and 2.5%, 1.3%, 0.8%, 
2.0%, 0.9%, and 3.8% for the VTE group, respectively. The corresponding risk 
ratios indicated that the risk of developing any complications was significantly 
higher for the recurrent VTE group compared to the VTE group (risk ratio [95% 
CI]: thrombocytopenia: 2.8 [2.4 - 3.3], superficial venous thrombosis: 3.3 [2.7 - 4.1], 
venous ulcer: 1.9 [1.4 - 2.6], pulmonary hypertension: 2.7 [2.2 - 3.2], stasis 
dermatitis: 1.5 [1.1 - 2.0], and venous insufficiency: 1.9 [1.6 - 2.2], all p-
values<0.01). CONCLUSIONS: In this large matched-cohort study, recurrent VTE 
patients had significantly higher risk of complications compared to VTE control 
patients.  
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OBJECTIVES: To compare the ability of four measures of patient retention in HIV 
expert care to predict clinical outcomes and health care utilization over 24 
months. METHODS: This retrospective study examined Veterans Health 
Administration (VHA) beneficiaries with HIV (ICD-9-CM codes 042 or V08) 
receiving expert care (HIV-1 RNA and CD4 tests within 1 week of each other) at 
VHA facilities from October 1, 2006 to September 30, 2008. Patients were 18-89 
years old with ≥24 months of VHA eligibility. Retention measures included: 
“appointments annual” (≥2 appointments annually at least 60 days apart), 
“appointments missed” (missed ≥25% of appointments), “appointments 
infrequent” (≥6 months without an appointment), and “appointments missed or 
infrequent” (missed ≥25% of appointments or ≥6 months without an 
appointment). Outcomes included: virologic suppression (HIV-1 RNA <500), CD4+ 
>500, development of an HIV-related condition, progression to AIDS, emergency 
room (ER) use, and hospitalization. Multivariable regression was used to 
determine associations between retention measures and outcomes. RESULTS: 
Study subjects (n=8,845) had a mean age of 52 years and 97% were male; 51% 
were black, 34% white, 11% other, and 4% unknown. At baseline, 64% of patients 
were virologically suppressed and 37% had a CD4+ >500. At 24 months, 82% were 
virologically suppressed and 46% had a CD4+ >500. During follow-up, 42% 
developed an HIV-related condition, 13.0% progressed to AIDS, 0.3% died, 48% 
visited the ER, and 28% were hospitalized. All four retention measures were 
associated with virologic suppression at 24 months. In addition, “appointments 
annual” was predictive of CD4+ >500 and “appointments missed” was associated 
with CD4+ >500, development of an HIV-related condition, progression to AIDS, 
ER use, and hospitalization. CONCLUSIONS: While all four retention measures 
had clinical value, “appointments missed” was the most accurate predictor of 
clinical outcomes and health care utilization at 24 months among VHA patients 
in HIV expert care.  
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OBJECTIVES: To evaluate clinical and economic burden among Medicare 
beneficiaries hospitalized for acute coronary syndrome (ACS) with comorbid 
atrial fibrillation (AF). METHODS: This study used data from the Medicare 
Current Beneficiary Survey. Patients with an incident hospitalization for ACS 
between March 1, 2002-December 31, 2006 and without similar events during 6 
months prior were included (date of the first event denoted as the index date). 
Comorbid AF was identified from Medicare claims during 6 months prior to the 
index date. Annual health care costs were summarized for the calendar year 
when the incident ACS event occurred. Incidence rates of subsequent 
cardiovascular (CV) hospitalization events and mortality was estimated and 
compared between patients with and without AF. Cox proportional hazards 
regressions were used to estimate the relative risk of AF on mortality and CV-
events adjusting for patient socio-demographic and clinical characteristics. 
Multi-stage sampling design and population weights were accounted for to yield 
national representative estimates. RESULTS: We identified 795 incident ACS 
patients representing over 2.5 million Medicare beneficiaries (mean age 76 years; 
49% male; 13% with AF). Compared with ACS patients who did not have AF, ACS-
AF patients had higher total health care costs ($66,586 vs. $48,031; P<0.001) and 
higher mortality after their ACS admission (574 vs. 277 deaths/1,000 person 
years; P <0.001). Among those discharged alive, patients with AF had a higher 
risk of subsequent CV-events (836 vs. 386 cases; P<0.001) if 1,000 patients were 
followed for 6 months. The adjusted results showed 59% higher risk of CV-events 
associated with AF (HR=1.590; 95% confidence interval: 1.247-2.026). 
CONCLUSIONS: Using a national representative sample of Medicare 
beneficiaries, we observed worse clinical and economic outcomes after 
hospitalization for ACS in patients with comorbid AF. The increased health care 
burden associated with AF underscores the importance of novel strategies to 
address management of this population.  
 
PHS4  
MULTIDISCIPLINARY PHYSICIAN CARE AND MORTALITY IN HEPATOCELLULAR 
CARCINOMA  
Chirikov VV1, Mullins CD1, Hanna NN2, Breunig IM1, Seal B3, Shaya FT1 
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland 
School of Medicine, Baltimore, MD, USA, 3Bayer HealthCare Pharmaceuticals, Inc., Pine Brook, NJ, 
USA  
OBJECTIVES: Multidisciplinary physician care has increased for many cancers 
yet little evidence exists for hepatocellular carcinoma (HCC). The study objective 
was to evaluate the association between multidisciplinary care and mortality  
in HCC. METHODS: Non-transplant treated patients with an HCC primary 
diagnosis in 2000-07 were followed-up in SEER-Medicare data. Multidisciplinary 
care was operationalized as the number of distinct specialists seen  
pre-treatment, including surgeons, radiology oncologists, intervention 
radiologists, hematologists/medical oncologists, gastroenterologists, and 
generalists. We built survival analysis models controlling for treatment, 
demographics, and clinical characteristics, and adjusted for selection/survival 
bias using inverse probability weighting and time-dependent covariates. 
RESULTS: Of 3320 treated HCC patients, 1323 (40%) saw one, 1250 (38%) saw  
two, and 747 (23%) saw three or more disciplines. Liver directed therapy  
and radiation was administered to a greater proportion of patients  
who encountered multiple specialists compared to those who saw a single 
discipline, who received more resection and chemotherapy. Multidisciplinary 
care was associated with stage 3 HCC and hepatitis C presence. In contrast, 
patients from rural areas and those diagnosed with stage 4 HCC saw fewer 
specialists prior to treatment. In time-dependent, propensity score adjusted 
survival analysis, patients who saw three or more disciplines had 10% (P=0.05) 
reduced mortality, compared to those who saw one discipline. When stratified 
by treatment received, patients on chemotherapy who saw three or more 
disciplines had 28% (P=0.002) reduced mortality. CONCLUSIONS: 
Multidisciplinary care for non-transplant HCC patients was associated with 
reduced mortality, particularly among chemotherapy recipients. While adjusting 
for selection and survival bias, our study may not fully capture the confounding 
effects of referral patterns among specialists on treatment and survival. Our 
findings provide evidence that may further support the development of models 
for coordinated health care delivery such as accountable care organizations 
(ACOs).  
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OBJECTIVES: A pharmacy-based inpatient diabetes management program  
was evaluated to determine if improved glycemic control could be achieved in a 
general medicine patient population. METHODS: A retrospective chart review of 
151 patients with blood glucose (BG) values outside the range 70-180 mg/dL  
was conducted. Observations for the baseline group (n=84) were derived from 
July 2010 and for the intervention group (n=67 ) in October 2010. The odds of  
poor glycemic control for patients in the intervention versus baseline groups 
were assessed by multivariate generalized estimating equations. These methods 
were also used to assess patient characteristics associated with poor glycemic 
control. RESULTS: Across all patients, no evidence was observed indicating  
the pharmacy program decreased the proportion of days spent out of  
the targeted blood glucose range [70-180 mg/dL: OR 0.91 (95% CI: 0.83 – 1.02);  
70-250 mg/dL: OR 1.03 (95% CI: 0.88 – 1.24)]. However, the subgroup of patients 
whose admission blood glucose was less than 200 mg/dL (55% of intervention 
group) experienced a significant reduction in days out of range for both  
ranges [70-180 mg/dL (OR: 0.72, 95% CI: 0.61– 0.88) and 70-250 mg/dL (OR: 0.5, 95% 
CI: 0.33 – 0.71)]. No improvement in glycemic control was observed in patients 
with an admission BG 200 mg/dL or greater. These patients had more disease- 
and social-related factors associated with poor glycemic control. CONCLUSIONS: 
A subpopulation, patients whose admission glucose was less than 200  
mg/dL, experienced improvement in glycemic control in the pharmacy-based 
program. The remaining patients were generally more complicated from  
a disease-state and social perspective and experienced no improvement.  
These patients may require a more intense, multi-disciplinary approach  
that is better matched to the constellation of factors responsible for their 
condition.  
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OBJECTIVES: The WHO with its MPOWER (Monitor Protect Offer Warn Enforce 
Raise) program is assisting the Kingdom of Saudi Arabia (KSA) one of the top 10 
cigarette importing countries with a 29% reported smoking prevalence among 
college Students. This study determined predictors of willingness to quit 
smoking among a cohort of Saudi male college students. METHODS: A cross-
sectional study was conducted in a cohort of male (≥18 years) college students 
that were recruited from three higher education institutions located in two 
regions within KSA. A pre-tested valid survey was used to collect data including 
socio-demographics, addiction level, presence of a smoker within the family, 
social pressure to quit, and number of past attempts to quit. The willingness-to-
quit variable was defined by asking participants if they had seriously thought 
about using smoking cessation strategies. Bivariate and logistic regression 
analyses were performed to assess factors associated with willingness to quit 
smoking. RESULTS: About 467 surveys were received (response rate 51%). 
Around 30% (n=104) of participants were smokers of which 72% (n=75) indicated 
their willingness to quit smoking. The average age of those willingness-to-quit 
was 22.6 (±2.2) years with an income of <$3200/year. The majority (95%) 
attempted to quit at least one time in the past. Only, willingness to quit smoking 
was significantly associated with past quit attempts (P=0.0017; OR=20.6; 
95%CI=3.1-137) after controlling for age, marital status, income, addictive level, 
current or former smoker family member, having a smoker friend, and social 
